Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma

PURPOSE: Alpelisib is a PI3K alpha (PI3Kα)-selective inhibitor approved for the treatment of hormone receptor–positive/HER2-negative (HR(+)/HER2(−)) PIK3CA-mutated advanced breast cancer (ABC) based on the SOLAR-1 trial, which defined 11 substitutions in exons 7, 9, and 20 in PIK3CA (SOLAR1m). We re...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, Hope S., Raskina, Kira, Schrock, Alexa B., Madison, Russell W., Graf, Ryon P., Sokol, Ethan S., Sivakumar, Smruthy, Lee, Jessica K., Fisher, Virginia, Oxnard, Geoffrey R., Tukachinsky, Hanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011882/
https://www.ncbi.nlm.nih.gov/pubmed/36321996
http://dx.doi.org/10.1158/1078-0432.CCR-22-2115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011882/
https://www.ncbi.nlm.nih.gov/pubmed/36321996
http://dx.doi.org/10.1158/1078-0432.CCR-22-2115

Ejemplares similares